Susana Llanos

Susana Llanos

Auto-generated profile, based on publicly available information

Susana Llanos

DNA Replication Group, Spanish National Cancer Research Center, Madrid, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
FTFrancisco Triana-Martínez
Francisco Triana-Martínez
PPPilar Picallos-Rabina
Pilar Picallos-Rabina
SSSabela Da Silva-Álvarez
Sabela Da Silva-Álvarez
FPFederico Pietrocola
Federico Pietrocola
SLSusana Llanos
Susana Llanos
Manuel ColladoManuel Collado
Manuel Collado
Compounds with specific cytotoxic activity in senescent cells, or senolytics, support the causal involvement of senescence in aging and offer therapeutic interventions. Here we report the identification of Cardiac Glycosides (CGs) as a family of compounds with senolytic activity. CGs, by targeting the Na+/K+ATPase pump, cause a disbalanced electrochemical gradient within the cell causing depolarization and acidification. Senescent cells present a slightly depolarized plasma membrane and higher concentrations of H+, making them more susceptible to the action of CGs. These vulnerabilities can be exploited for therapeutic purposes as evidenced by the in vivo eradication of tumors xenografted in mice after treatment with the combination of a senogenic and a senolytic drug. The senolytic effect of CGs is also effective in the elimination of senescence-induced lung fibrosis. This experimental approach allows the identification of compounds with senolytic activity that could potentially be used to develop effective treatments against age-related diseases.

16 July 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DMDaniel Muñoz‐Espín
Daniel Muñoz‐Espín
MRMiguel Rovira
Miguel Rovira
IGIrene Galiana
Irene Galiana
CGCristina Giménez
Cristina Giménez
BLBeatriz Lozano‐Torres
Beatriz Lozano‐Torres
MSManuel Serrano
Manuel Serrano
Senescent cells accumulate in multiple aging‐associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal β‐galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto‐oligosaccharides. We show that gal‐encapsulated fluorophores are preferentially released within senescent cells in mice. In a model of chemotherapy‐induced senescence, gal‐encapsulated cytotoxic drugs target senescent tumor cells and improve tumor xenograft regression in combination with palbociclib. Moreover, in a model of pulmonary fibrosis in mice, gal‐encapsulated cytotoxics target senescent cells, reducing collagen deposition and restoring pulmonary function. Finally, gal‐encapsulation reduces the toxic side effects of the cytotoxic drugs. Drug delivery into senescent cells opens new diagnostic and therapeutic applications for senescence‐associated disorders.

5 April 2001 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SLSusana Llanos
Susana Llanos
PCPaula A. Clark
Paula A. Clark
JRJanice Rowe
Janice Rowe
GPGordon Peters
Gordon Peters

17 June 2002 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SBSharon Brookes
Sharon Brookes
JRJanice Rowe
Janice Rowe
MRMargarida Ruas
Margarida Ruas
SLSusana Llanos
Susana Llanos
PCPaula A. Clark
Paula A. Clark
GPGordon Peters
Gordon Peters
The CDKN2A tumour suppressor locus encodes two distinct proteins, p16 INK4a and p14 ARF , both of which have been implicated in replicative senescence, the state of permanent growth arrest provoked in somatic cells by aberrant proliferative signals or by cumulative population doublings in culture. Here we describe primary fibroblasts from a member of a melanoma‐prone family who is homozygous for an intragenic deletion in CDKN2A . Analyses of the resultant gene products imply that the cells are p16 INK4a deficient but express physiologically relevant levels of a frameshift protein that retains the known functions of p14 ARF . Although they have a finite lifespan, the cells are resistant to arrest by oncogenic RAS. Indeed, ectopic expression of RAS and telomerase (hTERT) results in outgrowth of anchorage‐independent colonies that have essentially diploid karyotypes and functional p53. We find that in human fibroblasts, ARF is not induced demonstrably by RAS, pointing to significant differences between the proliferative barriers implemented by the CDKN2A locus in different cell types or species.

24 January 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SCSelim Chaib
Selim Chaib
JLJosé Alberto López-Domínguez
José Alberto López-Domínguez
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
NPNeus Prats
Neus Prats
IMInes Marin
Ines Marin
MSManuel Serrano
Manuel Serrano
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence.

1 October 2015 in Cell Reports
Verified
Journal Article
Open access
LMLucia Morgado-Palacin
Lucia Morgado-Palacin
GVGianluca Varetti
Gianluca Varetti
SLSusana Llanos
Susana Llanos
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
DMDolores Martinez
Dolores Martinez
MSManuel Serrano
Manuel Serrano
Diamond-Blackfan anemia (DBA) is characterized by anemia and cancer susceptibility and is caused by mutations in ribosomal genes, including RPL11. Here, we report that Rpl11-heterozygous mouse embryos are not viable and that Rpl11 homozygous deletion in adult mice results in death within a few weeks, accompanied by bone marrow aplasia and intestinal atrophy. Importantly, Rpl11 heterozygous deletion in adult mice results in anemia associated with decreased erythroid progenitors and defective erythroid maturation. These defects are also present in mice transplanted with inducible heterozygous Rpl11 bone marrow and, therefore, are intrinsic to the hematopoietic system. Additionally, heterozygous Rpl11 mice present increased susceptibility to radiation-induced lymphomagenesis. In this regard, total or partial deletion of Rpl11 compromises p53 activation upon ribosomal stress or DNA damage in fibroblasts. Moreover, fibroblasts and hematopoietic tissues from heterozygous Rpl11 mice present higher basal cMYC levels. We conclude that Rpl11-deficient mice recapitulate DBA disorder, including cancer predisposition.